Navigation Links
Few women take tamoxifen to prevent breast cancer
Date:2/7/2010

PHILADELPHIA Researchers with the National Cancer Institute (NCI) have found that the prevalence of tamoxifen use for the prevention of breast cancer among women without a personal history of breast cancer is very low.

Tamoxifen can reduce the risk of developing breast cancer in women who are at increased risk for developing the disease. Details of this survey are published in the February issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

The low prevalence of tamoxifen use may stem from various sources, which were not investigated in this study, according to the study's coauthor Andrew N. Freedman, Ph.D., chief of the Clinical and Translational Epidemiology Branch, Division of Cancer Control and Population Sciences, NCI.

However, he stressed that "counseling individual women about using tamoxifen to prevent breast cancer must include a patient's discussion with her physician about the drug's risks and benefits, as well as consideration of the patient's personal values, preferences, lifestyle and specific medical situation."

Lead author of this study Erika A. Waters, Ph.D., M.P.H., assistant professor at Washington University School of Medicine in St. Louis, and colleagues at the NCI wanted to gain an understanding of how many women aged 40 to 79 years were taking tamoxifen for the prevention of breast cancer. They answered this question using data from the National Health Interview Surveys from years 2000 and 2005, which are nationwide surveys designed to be representative of the entire United States. The surveys included more than 10,000 women for each year.

"Our results indicated that very few women were using tamoxifen to prevent breast cancer," said Waters. "However, we don't know exactly why."

The researchers found that the prevalence of tamoxifen use in this survey population was very low 0.2 percent in 2000 and 0.08 percent in 2005. The difference between the two years was not statistically meaningful, according to the researchers.

Freedman and Waters speculated that the drug's low uptake may be linked to many factors including the fact that tamoxifen is associated with several side effects. These side effects include hot flashes, sexual problems, uterine cancer, blood clots and cataracts. Other possible explanations that the researchers gave for the low uptake may be that physicians are unaware of the drug's availability, physicians are reluctant to prescribe it, patients are reluctant to take it, there is a lack of patient or physician education about the drug, or skepticism about whether the benefits outweigh the risks. It could also be that physicians and patients are, in fact, very educated and are making very informed decisions, according to the researchers.

"The decision to use a drug like tamoxifen in women at high-risk for, but who do not yet have a diagnosis of breast cancer is not easy. It is dependent upon the woman's personal choice, which can be influenced by many factors, not just her medical eligibility. There is no right answer," said Waters, who at the time of the study was a fellow in the Cancer Prevention Fellowship Program, Center for Cancer Training, NCI.

Susan Gapstur, Ph.D., M.P.H., vice president of epidemiology, American Cancer Society, and editorial board member of Cancer Epidemiology, Biomarkers & Prevention, said that "overall, these results provide an important snapshot of the very low uptake of tamoxifen for cancer prevention."

"Although the researchers speculate on a number of possible explanations, it remains unclear to what extent the low uptake might be attributed to physician reluctance to prescribe tamoxifen and/or patient reluctance to take it," said Gapstur.


'/>"/>

Contact: Tara Yates
tara.yates@aacr.org
267-646-0558
American Association for Cancer Research
Source:Eurekalert  

Related biology news :

1. New research shows genes of pregnant women and their fetuses can increase the risk of preterm labor
2. Finally, an excuse for pregnant women to eat bacon and eggs
3. Lower income women report more insurance-based discrimination during pregnancy, delivery
4. Many pregnant women avoid HIV screening in Africa
5. Toward explaining why hepatitis B hits men harder than women
6. Saliva proteins change as women age
7. 5 exercises can reduce neck, shoulder pain of women office workers
8. Women at risk from vitamin A deficiency
9. Attention-deficit/hyperactivity problems associated with low folate levels in pregnant women
10. Geologists studying groundwater arsenic levels in India empower Bengali women, children
11. The first men and women from the Canary Islands were Berbers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Few women take tamoxifen to prevent breast cancer
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
(Date:3/17/2016)... ABI Research, the leader in transformative ... market will reach more than $30 billion by ... Consumer electronics, particularly smartphones, continue to boost the ... reach two billion shipments by 2021 at a ... Research Analyst at ABI Research. "Surveillance is also ...
Breaking Biology News(10 mins):
(Date:5/2/2016)... ... , ... StarNet Communications Corp, ( http://www.starnet.com/ ) a leading publisher of remote ... modules to its flagship X-Win32 PC X server. The new modules enable X-Win32 ... PC over encrypted SSH. , Traditionally, users of PC X servers deploy the XDMCP ...
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, ... spinal surgical procedures, today announced the completion of a significant transaction and partnership ... and future customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading ...
(Date:4/29/2016)... ... ... Intelligent Implant Systems announced today that the two-level components for the Revolution™ ... States. These components expand the capabilities of the system and allow Revolution™ to ... of 2015, the company has seen significant sales growth in 1Q 2016, and the ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... and ongoing support for Connecticut's innovative, growing companies, today announced the launch of ... and financial technology (fintech) companies. , “VentureClash looks to attract the ...
Breaking Biology Technology: